Literature DB >> 19160030

Consumers' desire towards current and prospective reproductive genetic testing.

Feighanne Hathaway1, Esther Burns, Harry Ostrer.   

Abstract

As our knowledge and abilities in molecular genetics continues to expand, so does our ability to detect certain conditions/traits prenatally; however, it is unknown if this increase in scientific ability will be utilized by the consumers of genetic services. Our study gauges the consumers' opinion towards reproductive testing for diseases and enhancements. Prior to their initial visit with a genetic counselor, patients were asked to participate in a survey. These consumers were asked to indicate traits and conditions for which they would choose reproductive genetic testing. The majority of respondents would elect to have prenatal genetic testing for mental retardation (75%), deafness (54%), blindness (56%), heart disease (52%), and cancer (51%). Our results indicated that 49.3% would choose testing for a condition that resulted in death by 5 years of age, whereas only 41.1%, 24.9%, and 19% would choose testing for conditions that results in death by 20, 40, and 50 years of age, respectively. Most respondents did not desire testing for enhancements (e.g. 13% would choose testing for superior intelligence). Our study suggests that consumers desire more reproductive genetic testing than what is currently offered; however, their selection of tests suggests self-imposed limits on testing.

Entities:  

Mesh:

Year:  2009        PMID: 19160030     DOI: 10.1007/s10897-008-9199-3

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  28 in total

1.  Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.

Authors:  D Kronn; V Jansen; H Ostrer
Journal:  Arch Intern Med       Date:  1998-04-13

2.  Consequences of prenatal diagnosis of cystic fibrosis on the reproductive attitudes of parents of affected children.

Authors:  J Boué; F Muller; B Simon-Bouy; C Faure; A Boué
Journal:  Prenat Diagn       Date:  1991-04       Impact factor: 3.050

3.  Support for the availability of prenatal testing for neurological and psychiatric conditions in the psychiatric community.

Authors:  K K Milner; T Han; E M Petty
Journal:  Genet Test       Date:  1999

4.  Attitudes of young adults to prenatal screening and genetic correction for human attributes and psychiatric conditions.

Authors:  K K Milner; E E Collins; G R Connors; E M Petty
Journal:  Am J Med Genet       Date:  1998-03-05

5.  Attitudes towards reproductive issues and carrier testing among adult patients and parents of children with cystic fibrosis (CF).

Authors:  L Henneman; I Bramsen; T A Van Os; I E Reuling; H G Heyerman; J van der Laag; H M van der Ploeg; L P ten Kate
Journal:  Prenat Diagn       Date:  2001-01       Impact factor: 3.050

6.  Attitudes towards future testing for bipolar disorder susceptibility genes: a preliminary investigation.

Authors:  Ian Jones; Jane Scourfield; Fiona McCandless; Nick Craddock
Journal:  J Affect Disord       Date:  2002-09       Impact factor: 4.839

7.  Attitudes of healthcare professionals and parents regarding genetic testing for violent traits in childhood.

Authors:  E Campbell; L F Ross
Journal:  J Med Ethics       Date:  2004-12       Impact factor: 2.903

8.  Medical and lay attitudes towards genetic screening and testing in Finland.

Authors:  Hanna Toiviainen; Piia Jallinoja; Arja R Aro; Elina Hemminki
Journal:  Eur J Hum Genet       Date:  2003-08       Impact factor: 4.246

9.  Evaluation of a Tay-Sachs disease screening program.

Authors:  A A Gason; E Sheffield; A Bankier; M A Aitken; S Metcalfe; K Barlow Stewart; M B Delatycki
Journal:  Clin Genet       Date:  2003-05       Impact factor: 4.438

10.  Attitudes of persons at risk for Huntington disease toward predictive testing.

Authors:  S Kessler; T Field; L Worth; H Mosbarger
Journal:  Am J Med Genet       Date:  1987-02
View more
  8 in total

1.  Prenatal whole genome sequencing: just because we can, should we?

Authors:  Greer Donley; Sara Chandros Hull; Benjamin E Berkman
Journal:  Hastings Cent Rep       Date:  2012-06-20       Impact factor: 2.683

2.  Socializing the public: invoking Hannah Arendt's critique of modernity to evaluate reproductive technologies.

Authors:  Daniel Sperling
Journal:  Med Health Care Philos       Date:  2012-02

3.  Public perspectives on the use of preimplantation genetic diagnosis.

Authors:  William D Winkelman; Stacey A Missmer; Dale Myers; Elizabeth S Ginsburg
Journal:  J Assist Reprod Genet       Date:  2015-03-11       Impact factor: 3.412

Review 4.  Ethical, legal, social, and policy implications of behavioral genetics.

Authors:  Colleen M Berryessa; Mildred K Cho
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-02-28       Impact factor: 8.929

5.  The scope of prenatal diagnosis for women at increased risk for aneuploidies: views and preferences of professionals and potential users.

Authors:  Antina de Jong; Wybo J Dondorp; Anja Krumeich; Julie Boonekamp; Jan M M van Lith; Guido M W R de Wert
Journal:  J Community Genet       Date:  2012-11-09

6.  Response to Zlotogora and Meiner.

Authors:  Brett Baskovich; Susan Hiraki; Carole Oddoux; Harry Ostrer; Kinnari Upadhyay
Journal:  Genet Med       Date:  2015-12-10       Impact factor: 8.822

7.  Women's Attitudes Regarding Prenatal Testing for a Range of Congenital Disorders of Varying Severity.

Authors:  Mary E Norton; Sanae Nakagawa; Miriam Kuppermann
Journal:  J Clin Med       Date:  2014-01-21       Impact factor: 4.241

8.  Expanded genetic screening panel for the Ashkenazi Jewish population.

Authors:  Brett Baskovich; Susan Hiraki; Kinnari Upadhyay; Philip Meyer; Shai Carmi; Nir Barzilai; Ariel Darvasi; Laurie Ozelius; Inga Peter; Judy H Cho; Gil Atzmon; Lorraine Clark; Jin Yu; Todd Lencz; Itsik Pe'er; Harry Ostrer; Carole Oddoux
Journal:  Genet Med       Date:  2015-09-03       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.